Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality Among Young Adults Born Preterm and Early Term in 4 Nordic Nations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Assessment of Suicidal Behaviors Among Individuals With Autism Spectrum Disorder in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Development of visual attention from age 7 to age 12 in children with familial high risk for schizophrenia or bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dysregulated Lipid Metabolism Precedes Onset of Psychosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictors of remission from the ultra-high risk state for psychosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Importance: Genetic polymorphism of genes encoding the drug metabolizing enzymes, cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19), is associated with treatment failure of and adverse reactions to psychotropic drugs. The clinical utility of routine CYP2D6 and CYP2C19 genotyping (CYP testing) is unclear.

Objective: To estimate whether routine CYP testing effects the persistence of antipsychotic drug treatment.

Design, Setting, and Participants: This single-masked, 3-group randomized clinical trial included patients aged 18 years or older who had been diagnosed within the schizophrenic spectrum (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes, F20-F29) and not previously genotyped. A total of 669 of 1406 potentially eligible patients from 12 psychiatric outpatient clinics in Denmark were approached between July 2008 and December 2009. Overall, 528 patients were genotyped and randomly allocated to 1 of 3 study groups or exclusion in a sequence of 1:1:1:3 using a predictive enrichment design, aiming to double the proportion of poor or ultrarapid metabolizers for CYP2D6 or CYP2C19. Outcome measurements were recorded at baseline and 1-year follow-up. Data analysis was performed in December 2012 and updated March 2019.

Interventions: The trial included 2 intervention groups, where antipsychotic drug treatment was guided by either CYP test (CYP test-guided [CTG]) or structured clinical monitoring (SCM), in which adverse effects and factors influencing compliance were systematically recorded at least once quarterly, and 1 control group.

Main Outcomes and Measures: Primary outcome was antipsychotic drug persistence, ie, days to first modification of the initial treatment. Secondary outcomes were number of drug and dose changes, adverse effects, and psychotic symptoms, ie, hallucinations and delusions.

Results: A total of 528 participants were genotyped, and 311 (median [interquartile range {IQR} age, 41 [30-50] years; 139 [45%] women; median [IQR] duration of illness, 6 [3-13] years) were randomly allocated to 1 of 3 study groups. Overall, 61 participants (20%) were extreme metabolizers. There was no difference in antipsychotic drug persistence between the CTG group and the control group (hazard ratio [HR], 1.02; 95% CI, 0.71-1.45) or SCM and the control group (HR, 0.88; 95% CI, 0.61-1.26). Subanalyses among extreme metabolizers showed similar results (CTG: HR, 0.99; 95% CI, 0.48-2.03; SCM: HR, 0.93; 95% CI, 0.44-1.96).

Conclusions and Relevance: The results of this randomized clinical trial do not support routine CYP testing in patients with schizophrenia.

Trial Registration: ClinicalTrials.gov Identifier: NCT00707382.

OriginalsprogEngelsk
TidsskriftJAMA network open
Vol/bind3
Udgave nummer12
Sider (fra-til)e2027909
ISSN2574-3805
DOI
StatusUdgivet - 1 dec. 2020

ID: 61629248